Cancer Research and Treatment

Case Reports

Breast Cancer Metastasis to the Stomach Resembling Early Gastric Cancer: Wan Kyu Eo; Cancer Res Treat. 2008;40(4):207-210. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.207

Breast cancer metastases to the stomach are infrequent, with an estimated incidence rate of approximately 0.3%. Gastric metastases usually are derived from lobular rather than from ductal breast cancer. The most frequent type of a breast cancer metastasis as seen on endoscopy to the stomach is linitis plastica; features of a metastatic lesion that resemble early gastric cancer (EGC) are extremely rare. In this report, we present a case of a breast cancer metastasis to the stomach from an infiltrating ductal carcinoma (IDC) of the breast in a 48-year-old woman. The patient had undergone a left modified radical mastectomy with axillary dissection nine years prior. A gastric endoscopy performed for evaluation of nausea and anorexia showed the presence of a slightly elevated mucosal lesion in the cardia, suggestive of a type IIa EGC. A histological examination revealed nests of a carcinoma in the subepithelial lymphatics, and immunohistochemical staining for estrogen receptor was positive. This is an extremely rare case with features of type IIa EGC, but the lesion was finally identified as a cancer metastasis to the cardia of the stomach from an IDC of the breast.

Citations

Citations to this article as recorded by

Radiologic patterns of distant organ metastasis in advanced breast cancer patients: Prospective review of computed tomography images
Bashiru Babatunde Jimah, Emmanuella Amoako, Emmanuel Owusu Ofori, Patrick Kafui Akakpo, Luke Adagrah Aniakwo, Kofi Ulzen‐Appiah, Emmanuel Gustav Imbeah, Martin Tangnaa Morna, Patience Koggoh, Harry Akligoh, Randy Tackie, Aida Manu, Lily Paemka, Benjamin D
Cancer Reports.2024;[Epub] CrossRef
Case report: Cutaneous metastases as a first manifestation from breast cancer with concurrent gastric metastases
Lulu Xu, Congcong Wang, Xiaoling Yang, Liangliang Dong
Frontiers in Pharmacology.2024;[Epub] CrossRef
Breast cancer metastasis to the stomach mimicking early gastric cancer
Kosuke Tanaka, Yohei Yabuuchi, Daisuke Yamashita, Tetsuro Inokuma
JGH Open.2023; 7(9): 667. CrossRef
De novo gastric metastasis from invasive lobular carcinoma of the breast: report of three cases and literature review
Jessica Gonzalez Suerdieck, Juliana Alves Souza, Mateus Mattioni, Almir Galvão Vieira Bitencourt
Mastology.2022;[Epub] CrossRef
S1847 Breast Cancer Metastases to the Gastrointestinal Tract: A Case Report
Vimal Bodiwala, Akhtar Cheema, Elliot Bigajer
American Journal of Gastroenterology.2021; 116(1): S813. CrossRef
Breast cancer metastasizing to the stomach mimicking primary gastric cancer: A case report
Kwangil Yim, Sang Mi Ro, Jieun Lee
World Journal of Gastroenterology.2017; 23(12): 2251. CrossRef
Metastatic pattern of invasive lobular carcinoma of the breast-Emphasis on gastric metastases
Ali El-Hage, Carolanne Ruel, Wahiba Afif, Hussein Wissanji, Jean-Charles Hogue, Christine Desbiens, Guy Leblanc, Éric Poirier
Journal of Surgical Oncology.2016; 114(5): 543. CrossRef
Breast Cancer Metastasis to the Stomach That Was Diagnosed after Endoscopic Submucosal Dissection
Masahide Kita, Masashi Furukawa, Masaya Iwamuro, Keisuke Hori, Yoshiro Kawahara, Naruto Taira, Tomohiro Nogami, Tadahiko Shien, Takehiro Tanaka, Hiroyoshi Doihara, Hiroyuki Okada
Case Reports in Gastrointestinal Medicine.2016; 2016: 1. CrossRef
BREAST CANCER METASTASIS IN THE STOMACH: WHEN THE GASTRECTOMY IS INDICATED ?
Marcus Vinicius Rozo RODRIGUES, Valdir TERCIOTI-JUNIOR, Luiz Roberto LOPES, João de Souza COELHO-NETO, Nelson Adami ANDREOLLO
ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2016; 29(2): 86. CrossRef
Synchronous Primary Carcinoma of Breast and Ovary Versus Ovarian Metastases
Budhi S. Yadav, S.C. Sharma, Tyler P. Robin, Sharon Sams, Anothony D. Elias, Virginia Kaklamani, P. Kelly Marcom, Sara Schaefer, Gloria J. Morris
Seminars in Oncology.2015; 42(2): e13. CrossRef
Clinicopathological features of gastric metastasis from breast cancer in three cases
Kenta Koike, Kenji Kitahara, Mayumi Higaki, Masako Urata, Fumio Yamazaki, Hirokazu Noshiro
Breast Cancer.2014; 21(5): 629. CrossRef

9,009 View
142 Download
11 Crossref

A Case of Multiple Intussusceptions in the Small Intestine Caused by Metastatic Renal Cell Carcinoma: Wan Kyu Eo, Gou Young Kim, Sung Il Choi; Cancer Res Treat. 2008;40(2):97-99. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.97

Abstract PDF PubReader ePub

Renal cell carcinoma (RCC) may metastasize to almost any organ, but metastasis to the small bowel is rare. Small bowel metastasis from RCC can induce obstruction or bleeding, and perforation can also be induced in rare case. Yet RCC metastasis to the small bowel is unlikely to be a direct cause of intussusceptions. A few cases of intussusceptions caused by small intestinal metastasis of RCC have been reported, but multiple small intestinal intussusceptions are extremely rare. We report here on a 47-year-old male patient who presented to the emergency room with acute abdominal pain. He had undergone radical nephrectomy 2 years previously due to left RCC. The abdominal CT scan revealed enhanced masses with the "target" sign that suggested enteric intussusceptions in the jejunum. Eight pedunculated masses within the small intestinal lumen led to intussusceptions at 30 and 150 cm distal to Treitz ligament. Three segmental resections of the small intestine and functional end to end anastomosis were done. The patient recovered uneventfully from this operation. To the best of our knowledge, this is the 1^st report of metastases from RCC that presented as synchronous intraluminal polypoid tumors, and these tumors served as the lead points for two intussusceptions in the jejunum.

Citations

Citations to this article as recorded by

Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy
Yidan Lou, Kaibo Guo, Song Zheng
Frontiers in Oncology.2023;[Epub] CrossRef
Solitary metastasis of clear cell renal cell carcinoma in the small intestine 10 years after right nephrectomy
M.D. Budurova, N.V. Vorobyov, S.I. Poluektov, V.S. Surkova, N.A. Grishin, K.A. Turupaev, M.A. Chernichenko, A.B. Ryabov
Onkologiya. Zhurnal imeni P.A.Gertsena.2023; 12(6): 57. CrossRef
Metastatic disease masquerading as small intestinal tumoural masses: two case reports and literature review
Jovell Xing Yi Sim, Ilyana Huda Binte Mohamed Hussain, Wei Qiang Leow
Proceedings of Singapore Healthcare.2017; 26(4): 263. CrossRef
Severe blood loss anaemia and recurrent intussusceptions as first presentation of bowel metastatic renal cell carcinoma: A case report and review of the literature
Claudia Trojaniello, Maria Giuseppa Vitale, Biagio Trojaniello, Maria Luisa Lentini Graziano, Mariarosa Coccaro, Giacomo Cartenì, Vincenzo Montesarchio
Molecular and Clinical Oncology.2017; 7(4): 654. CrossRef
Small bowel intussusception from renal cell carcinoma metastasis: a case report and review of the literature
Gabriele Bellio, Tommaso Cipolat Mis, Gladiola Kaso, Roberto Dattola, Biagio Casagranda, Marina Bortul
Journal of Medical Case Reports.2016;[Epub] CrossRef
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review
Morena Fasano, Carminia Maria Della Corte, Giovanni Vicidomini, Valerio Scotti, Pier Francesco Rambaldi, Alfonso Fiorelli, Marina Accardo, Ferdinando De Vita, Mario Santini, Fortunato Ciardiello, Floriana Morgillo
Oncology Letters.2016; 12(6): 4505. CrossRef
Triple jejuno-jejunal intussusception due to metastatic renal cell carcinoma
A.-S. Massy Budmiger, V. Nagy, S. Hurlimann, J. Metzger
Journal of Surgical Case Reports.2015; 2015(4): rjv047. CrossRef
An obscure cause of gastrointestinal bleeding: Renal cell carcinoma metastasis to the small bowel
Robyn L. Gorski, Salah Abdel Jalil, Manver Razick, Ala' Abdel Jalil
International Journal of Surgery Case Reports.2015; 15: 130. CrossRef
Recurrent Renal Cell Carcinoma with Synchronous Tumor Growth in Azygoesophageal Recess and Duodenum: A Rare Cause of Anemia and Upper Gastrointestinal Bleeding
Vamshidhar R. Vootla, Muhammad Kashif, Masooma Niazi, Suresh K. Nayudu
Case Reports in Oncological Medicine.2015; 2015: 1. CrossRef
Atypical Multiple Ileum Metastases of Renal Cell Carcinoma
Raffaele Longo, Domenico Gattuso, Roberto Luchetti, Carlo Giannetti, Alessandro Mero, Cinzia Bernardi, Giampietro Gasparini
Journal of Gastrointestinal Cancer.2013; 44(4): 477. CrossRef
Enduring Response to Everolimus as Third-Line Therapy in a Patient With Advanced Renal Cell Carcinoma, Including Small-Bowel Metastases: Loss of FHIT but Normal VHL Gene Status
Reuben J. Broom, Imogen Caldwell, Fritha Hanning, Peter Fong, Sanjeev Deva, Paul Oei
Clinical Genitourinary Cancer.2012; 10(3): 202. CrossRef
A case of wedge resection of duodenum for massive gastrointestinal bleeding due to duodenal metastasis by renal cell carcinoma
Hongzhi Zhao, Keqiang Han, Jing Li, Ping Liang, Guohua Zuo, Yu Zhang, Hongyan Li
World Journal of Surgical Oncology.2012;[Epub] CrossRef
Malignant Pleural Mesothelioma Presenting as an Acute Surgical Abdomen due to Metastatic Jejunal Perforation
Kyoko Gocho, Kazutoshi Isobe, Kyohei Kaburaki, Yoshiko Honda, Aki Mitsuda, Yoshikiyo Akasaka, Nagato Shimada, Keigo Takagi, Sakae Homma
Internal Medicine.2010; 49(6): 597. CrossRef

10,215 View
69 Download
13 Crossref

Original Articles

MINE (mesna, ifosfamide, mitoxantrone, etoposide) Chemotherapy as a Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma: Seong Hoon Chang, Yang Soo Kim, Wan Kyu Eo; Cancer Res Treat. 2002;34(2):145-152. Published online April 30, 2002; DOI: https://doi.org/10.4143/crt.2002.34.2.145

Abstract PDF

PURPOSE
The prognosis of non-Hodgkin's lymphoma (NHL) is disappointing for patients who experience primary treatment failure or relapse after an initial response. Patients in relapse may respond again to chemotherapy, however the time to disease progression becomes shorter and eventually the disease becomes resistant. The aim of this study was to evaluate the efficacy and safety of the MINE regimen in the treatment of patients with relapsed or refractory NHL. Material and Methods: Forty-three pretreated patients with a median age of 56 years were enrolled into the study between October 1995 and June 2000. Most patients (60.5%) had a performance status of 0 to 1, and a diffuse large cell subtype (55.8%). Seventy-four percent of patients had stage III or IV disease at the start of MINE treatment. Eighteen (41.9%) patients had complete response, 5 (11.6%) had partial response, and 20 (46.5%) had failed to respond to prior therapy. Ifosfamide 4 g/m2 was divided over 3 days and administered IV over a 1 hour period. Mitoxantrone 8 mg/m2 was administered as a short IV infusion on day 1. Etoposide (65 mg/m2/day) was infused over 1 hour on days 1 to 3. A total of 144 cycles was administered, with a mean of 3.34 cycles per patient (range, 1-8). The mean relative dose intensity was 87.4%.
RESULTS
1) Nine patients achieved a complete response and nine patients achieved a partial response, resulting in an overall response rate of 43.8% of the 41 assessable patients. 2) The median survival time was 6 months (95% CI, 4 to 8 months), and the median time to failure was 5 months (95% CI, 3 to 7 months). 3) A statistically significant association with complete response rates was found for complete response to prior therapy (p=0.049). The significant factors for overall survival were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.012, respectively). The significant factors for time to treatment failure were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.044, respectively). 4) The main result of toxicity of MINE was bone marrow suppression.
CONCLUSION
The response to MINE chemotherapy and serum 2-microglobulin were both independent prognostic factors for overall survival and time to treatment failure. As the median time to treatment failure for complete responses was 14 months, the best use of this regimen could be in a strategy that includes prompt consolidation of a complete response with intense chemotherapy, with or without hematopoietic stem cell rescue.

Citations

Citations to this article as recorded by

Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy–intolerant lymphoma patients
Akihiro Ohmoto, Shigeo Fuji
Expert Review of Anticancer Therapy.2021; 21(7): 715. CrossRef

5,718 View
167 Download
1 Crossref

Results of Treatment with ProMACE - CytaBOM Regimen for Aggressive Non - Hodgkins Lymphoma: Wan Kyu Eo; J Korean Cancer Assoc. 2000;32(1):168-177.

Abstract PDF: PURPOSE
Despite intensive search for the optimal combination chemotherapy for aggres- sive non-Hodgkins lymphoma (NHL), the CHOP regimen is still the standard therapy. We investigated the clinical efficacy of ProMACE-CytaBOM, a third generation regimen, in patients with advanced aggressive NHL.
MATERIALS AND METHODS
We prospectively analyzed the therapeutic approach and the outcome in 33 patients with previously untreated aggressive NHL enrolled into the protocol from June 1994 to June 1997.
RESULTS
Objective response was achieved in 93.9% of the patients. Complete response (CR) and partial response were 54.5% and 39.4%, respectively. The mean time to CR was 75.4 days. CR rate was significantly lower in patients aged 50 years or more (31.3% vs 76.5%, p=0.009). Five year overall (OS) and failure-free survival (FFS) rate were 56.1% and 47.2%, respectively. The age, attainment of CR, and mean relative dose intensity influenced OS significantly (p=0.002, p=0.005 and p=0.039, respectively). The age and attainment of CR influenced FFS significantly (p=0.001 and p=0.003, respec- tively). In patients aged 50 or more, mean relative dose intensity of less than 72% was more frequent than younger age group (73.3% vs 33.3%, p=0.003). There was one toxic death (3.0%).
CONCLUSION
The survival rate of present study was similar to that of previously report concerning ProMACE-CytaBOM. The outcome of elderly NHL patients was poor, and dose intensity may be correlated with the outcome.

3,264 View
26 Download

First
Prev
Page of 1
Next
Last

Search